Matthew Pauls
Matthew Pauls's purchase track record
How the stock did after each of Matthew Pauls's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 12/2/2021 | SVRA | $18K | +1.8% | +21.1% | -8.8% |
| 11/18/2021 | SVRA | $24K | +5.5% | +26.4% | -17.1% |
| 8/17/2021 | SVRA | $32K | -5.1% | +3.4% | +0.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Savara Stock Mentioned Among Gainers in Market Roundup. Savara Inc. was included in a recent market roundup highlighting stocks that moved higher on Wednesday. The company's shares are currently trading near a key support level, which may have contributed to the short-term price movement noted in the report. This mention reflects general market activity rather than a specific corporate announcement.
Transaction History
| PTHS | ▼ Sell | Open Market | 786 | $17K | 10/2/2026 | View on chart |
| PTHS | ▼ Sell | Open Market | 692 | $18K | 7/2/2026 | View on chart |
| PTHS | ▼ Sell | Open Market | 94 | $3K | 7/2/2026 | View on chart |
| PTHS | ▼ Sell | Open Market | 415 | $9K | 4/2/2026 | View on chart |
| PTHS | ▼ Sell | Open Market | 371 | $8K | 4/2/2026 | View on chart |
| SVRA | ▼ Sell | Gift | 128,995 | $0 | 12/16/2025 | View on chart |
| SVRA | ▼ Sell | Tax Withholding | 195,705 | $1.4M | 12/14/2025 | View on chart |
| SVRA | ▼ Sell | Gift | 23,629 | $0 | 12/10/2025 | View on chart |
| PTHS | ▼ Sell | Gift | 9,542 | $0 | 12/10/2025 | View on chart |
| PTHS | ▲ Buy | Option Exercise | 2,123 | $0 | 10/2/2025 | View on chart |
| PTHS | ▲ Buy | Option Exercise | 8,493 | $0 | 7/2/2025 | View on chart |
| SVRA | ▼ Sell | Open Market | 54,702 | $181K | 12/16/2024 | View on chart |
| SVRA | ▼ Sell | Tax Withholding | 92,593 | $297K | 12/13/2024 | View on chart |
| SVRA | ▲ Buy | Grant | 400,000 | $0 | 12/12/2024 | View on chart |
| SVRA | ▼ Sell | Open Market | 84,000 | $396K | 12/28/2023 | View on chart |
| SVRA | ▼ Sell | Gift | 19,000 | $0 | 12/28/2023 | View on chart |
| SVRA | ▲ Buy | Grant | 450,000 | $0 | 12/14/2023 | View on chart |
| SVRA | ▼ Sell | Tax Withholding | 109,680 | $488K | 12/14/2023 | View on chart |
| SVRA | ▲ Buy | Grant | 325,000 | $0 | 12/13/2022 | View on chart |
| SVRA | ▼ Sell | Tax Withholding | 62,318 | $77K | 12/31/2021 | View on chart |
| SVRA | ▲ Buy | Grant | 400,000 | $0 | 12/14/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 6,500 | $7K | 12/8/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 10,000 | $11K | 12/2/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 10,000 | $11K | 11/19/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 2,150 | $2K | 11/19/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 10,000 | $11K | 11/18/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 11,900 | $14K | 8/18/2021 | View on chart |
| SVRA | ▲ Buy | Open Market | 15,000 | $18K | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Pelthos Expands Coverage for ZELSUVMI Topical Gel
Pelthos Therapeutics announced that its topical gel ZELSUVMI® will now be covered by more insurance plans. The broader formulary coverage could make the product more accessible to patients. This change may support the company’s sales growth for the drug. The update follows the company’s recent progress in bringing the therapy to market.
Pelthos Expands Coverage for ZELSUVMI Topical Gel. Pelthos Therapeutics announced that its topical gel ZELSUVMI® will now be covered by more insurance plans. The broader formulary coverage could make the product more accessible to patients. This change may support the company’s sales growth for the drug. The update follows the company’s recent progress in bringing the therapy to market.